.jpg)
Deutsche Börse: Oasmia Pharmaceutical (ISIN: SE0000722365) joined the General Standard of the Frankfurt Stock Exchange on 24 January. 52,079,341 registered shares without par value were listed. The initial listing price was €1.85.
Silvia Quandt & Cie AG is the issue bank, designated sponsor is biw Bank für Investments und Wertpapiere AG and lead broker is Bid & Ask Financial Services GmbH.
“We are delighted that a Swedish company from the Pharma & Healthcare sector is now listed in Frankfurt,” said Barbara Georg, Head of Listing & Issuer Services at Deutsche Börse. “The sector has an international focus and the Frankfurt Stock Exchange is connected to investors all over the world.”
“It feels exciting to be part of one of the largest stock markets in the world and we can now expand our business network considerably,” said Julian Aleksov, CEO of Oasmia Pharmaceutical.
According to information provided by the company, Oasmia Pharmaceutical focuses on developing a new generation of pharmaceuticals for the oncology sector.
Oasmia Pharmaceutical ist he 301st company in the General Standard of the Frankfurt Stock Exchange. The General Standard is part of the EU-regulated market.
